Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice

• Published in: PloS one Vol. 12; no. 2; p. e0172161
• Main Authors: Carter, Alexis Y, Letronne, Florent, Fitz, Nicholas F, Mounier, Anais, Wolfe, Cody M, Nam, Kyong Nyon, Reeves, Valerie L, Kamboh, Hafsa, Lefterov, Iliya, Koldamova, Radosveta
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 27.02.2017; Public Library of Science (PLoS)
• Subjects: ABCA1 protein; Agonists (Biochemistry); Alzheimer's disease; Amyloid beta-Peptides - metabolism; Animals; Apolipoprotein E3 - genetics; Apolipoprotein E4; Apolipoprotein E4 - genetics; Apolipoproteins; ATP Binding Cassette Transporter 1 - genetics; ATP-binding protein; Behavior, Animal; Biology and Life Sciences; Brain; Brain - metabolism; Cholesterol; Cluster Analysis; Cognitive ability; Data processing; Efflux; Fear; Female; Gene expression; Gene set enrichment analysis; Genomes; Haploinsufficiency; Heterozygote; Humans; Isoforms; Laboratory animals; Ligands; Liver; Liver X receptors; Liver X Receptors - agonists; Male; Maze Learning; Medicine and Health Sciences; Memory; Memory Disorders - metabolism; Mice; Mice, Transgenic; Microtubules - metabolism; Occupational health; Oligomers; Phenotype; Phospholipids; Physiological aspects; Plasma; Receptors; Research and Analysis Methods; Restoration; Retinoid X receptors; Rodents; Software; Studies; Transcription; Transcription factors; Transcriptome; Transgenic animals; Transgenic mice; Up-Regulation
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0172161

ATP-binding cassette transporter A1 (ABCA1) controls cholesterol and phospholipid efflux to lipid-poor apolipoprotein E (APOE) and is transcriptionally controlled by Liver X receptors (LXRs) and Retinoic X Receptors (RXRs). In APP transgenic mice, lack of Abca1 increased Aβ deposition and cognitive deficits. Abca1 haplo-deficiency in mice expressing human APOE isoforms, increased level of Aβ oligomers and worsened memory deficits, preferentially in APOE4 mice. In contrast upregulation of Abca1 by LXR/RXR agonists significantly ameliorated pathological phenotype of those mice. The goal of this study was to examine the effect of LXR agonist T0901317 (T0) on the phenotype and brain transcriptome of APP/E3 and APP/E4 Abca1 haplo-deficient (APP/E3/Abca1+/- and APP/E4/Abca1+/-) mice. Our data demonstrate that activated LXRs/RXR ameliorated APOE4-driven pathological phenotype and significantly affected brain transcriptome. We show that in mice expressing either APOE isoform, T0 treatment increased mRNA level of genes known to affect brain APOE lipidation such as Abca1 and Abcg1. In both APP/E3/Abca1+/- and APP/E4/Abca1+/- mice, the application of LXR agonist significantly increased ABCA1 protein level accompanied by an increased APOE lipidation, and was associated with restoration of APOE4 cognitive deficits, reduced levels of Aβ oligomers, but unchanged amyloid load. Finally, using Gene set enrichment analysis we show a significant APOE isoform specific response to LXR agonist treatment: Gene Ontology categories "Microtubule Based Process" and "Synapse Organization" were differentially affected in T0-treated APP/E4/Abca1+/- mice. Altogether, the results are suggesting that treatment of APP/E4/Abca1+/- mice with LXR agonist T0 ameliorates APOE4-induced AD-like pathology and therefore targeting the LXR-ABCA1-APOE regulatory axis could be effective as a potential therapeutic approach in AD patients, carriers of APOEε4.